Sponsor Overview
Explore verified public information about Blueprint Medicines Corporation's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“We are committed to providing early access programs for our investigational medicines for these patients most in need, while maintaining our primary focus on moving our investigational medicines through clinical trials and ultimately toward regulatory approvals.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 3 supporting sources.
Conditions: Solid Tumors
Conditions: GIST
Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Please see our Pre-Approval Access Policy on our website Available Therapies via Single-Patient EA Investigational medicine, avapritinib (formerly known as BLU-285) See also: https://clinicaltrials.gov/ct2/show/NCT03862885?term=avapritinib&draw=2&rank=4 Investigational medicine, pralsetinib (formerly known as BLU-667) See also: https://clinicaltrials.gov/ct2/show/NCT04204928?term=pralsetinib&draw=2&rank=1 Disease/Category-Specific EA Policies/Criteria Avapritinib: Advanced gastrointestinal stromal tumors (GIST), advanced or smoldering systemic mastocytosis (SM), or another tumor type with a mutation in exon 17 of the KIT gene or in exon 18 of the PDGFRA gene Pralsetinib: Advanced Non-Small Cell Lung Cancer (NSCLC) or Medullary Thyroid Cancer (MTC)
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.